Presidio Pharmaceuticals Status
The company raised $21.83 million of Series D venture funding from Crown Predator Holdings, Five Corners Capital and other undisclosed investors on June 13, 2014, putting the pre-money valuation at $15 million.
Developer of small-molecule antiviral therapeutics designed to treat hepatitis C virus (HCV) infection. The company's antiviral therapeutics offer once-daily oral dosing and can be combined with other classes of HCV antivirals to combat viral resistance, enabling patients to access effective drug therapies against a variety of known HCV genotypes.
Year Founded
2006
Employees
12
General Information
-
Website
-
Business Status
Generating Revenue
-
Ownership Status
Privately Held (backing)
-
Financing Status
Venture Capital-Backed
Presidio Pharmaceuticals News and Updates
TEC Announces Expanded Alliance With Rio Grande Electric ...
PR Newswire | February 16, 2023
Identiv Enters Exclusive Strategic Manufacturing and Channel Agreement with Trace-ID
Yahoo Finance | February 15, 2023
GovExec and FCW Announce 2023 Federal 100 Winners
PR Newswire | February 10, 2023
Schneider Electric Hosts Texas State Senator César Blanco (SD29 ...
PR Newswire | February 10, 2023
Darolutamide Maintenance in Patients With Metastatic Castration ...
ASCO Journals | February 8, 2023
Anthony Lloyd
Technology Magazine | February 6, 2023
Presidio Pharmaceuticals's Verticals
Presidio Pharmaceuticals Primary Industry Sector / Group / Code
Presidio Pharmaceuticals's Trends
Presidio Pharmaceuticals Metrics
Growth Rate
Headquarters
-
HQ Address Line 11700 Owens Street
-
HQ Address Line 2Suite 585
-
HQ CitySan Francisco
-
HQ State/ProvinceCalifornia
-
HQ Post Code94158
-
HQ CountryUnited States
Presidio Pharmaceuticals's Keywords
mood_badFeed is empty.
Add a review